DR. REDDY S LABORATORIES (DRREDDY) financials

DR. REDDY S LABORATORIES (DRREDDY) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.

Market Cap: ₹1,02,616Cr.
Current Price: ₹1,229
Stock P/E: 155
ROE: 10.2%
ROCE: 12.1%
Book Value: ₹376
Dividend Yield: 0.65%
52W High / Low: ₹1,415/1,080

In Jun 2026, DR. REDDY S LABORATORIES (DRREDDY) reported sales ₹5,137 Cr and net profit ₹405 Cr.

Annual TTM: sales ₹17,860 Cr, net profit ₹663 Cr.

Shareholding: Promoters 26.63% (Jun 2026), FIIs 20.67% (Jun 2026), DIIs 31.75% (Jun 2026), Public 20.76% (Jun 2026), Others 0.20% (Jun 2026).

DRREDDY quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	6,696	5,015	5,563	7,810	4,619	4,283	3,822	5,137
Expenses	3,975	3,823	4,120	3,972	4,138	4,183	4,322	4,689
Operating Profit	2,722	1,192	1,443	3,837	480	100	-500	447
OPM %	41%	24%	26%	49%	10%	2.3%	-13%	9%
Other Income	208	235	414	398	364	360	567	440
Interest	28	43	31	19	33	41	54	73
Depreciation	260	265	264	280	295	314	318	318
Profit before tax	2,641	1,119	1,562	3,936	516	104	-306	497
Tax %	29%	24%	23%	25%	25%	13%	-28%	19%
Net Profit	1,882	849	1,201	2,961	387	91	-219	405
EPS in Rs	22.56	10.18	14.39	35.48	4.64	1.09	-2.63	4.85
Raw PDF	—	—	—	—	—	—	—	—

DRREDDY profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	11,850	13,349	14,405	16,962	19,484	23,115	20,533	17,860
Expenses	8,967	10,212	11,803	12,724	13,557	15,691	16,615	17,332
Operating Profit	2,883	3,137	2,602	4,238	5,926	7,425	3,917	527
OPM %	24%	24%	18%	25%	30%	32%	19%	3.0%
Other Income	730	801	474	568	862	961	1,690	1,732
Interest	48	47	38	17	22	110	148	202
Depreciation	789	835	814	923	976	1,039	1,207	1,245
Profit before tax	2,776	3,056	2,224	3,866	5,791	7,236	4,251	812
Tax %	-6%	28%	27%	32%	25%	26%	24%	—
Net Profit	2,938	2,186	1,623	2,613	4,342	5,349	3,220	663
EPS in Rs	35.36	26.29	19.51	31.38	52.06	64.11	38.58	7.95
Dividend Payout %	14%	19%	31%	26%	15%	12%	21%	—

DRREDDY balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	83	83	83	83	83	83	83	84
Reserves	12,601	15,109	16,900	18,253	20,391	24,157	28,773	31,282
Borrowings	1,065	1,457	1,214	2,205	51	793	3,493	5,737
Other Liabilities	2,499	2,827	3,431	3,954	4,850	5,326	5,941	6,500
Total Liabilities	16,248	19,476	21,630	24,496	25,375	30,359	38,291	43,602
Fixed Assets	4,683	4,434	5,844	6,150	7,195	7,589	8,232	10,730
CWIP	400	412	901	1,200	924	1,211	2,197	1,369
Investments	3,934	5,486	4,649	4,937	7,440	7,321	13,194	15,595
Other Assets	7,231	9,145	10,235	12,208	9,815	14,239	14,668	15,908
Total Assets	16,248	19,476	21,630	24,496	25,375	30,359	38,291	43,602

DRREDDY cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	2,762	1,839	3,514	1,339	5,053	3,450	4,225	4,660
Cash from Investing Activity	-546	-1,689	-1,454	-1,990	-3,403	-3,429	-5,697	-5,760
Cash from Financing Activity	-2,223	-224	-794	506	-2,697	68	1,591	1,117
Net Cash Flow	-8	-74	1,266	-146	-1,047	89	118	18
Free Cash Flow	2,197	1,371	2,910	-18	3,506	1,944	1,791	1,846
CFO/OP	128%	80%	126%	70%	138%	80%	78%	143%

DRREDDY shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	26.64%	26.64%	26.64%	26.64%	26.64%	26.64%	26.63%	26.63%
FIIs	27.53%	26.85%	25.75%	25.33%	24.69%	22.34%	21.14%	20.67%
DIIs	21.48%	22.89%	25.63%	26.73%	27.99%	30.44%	30.72%	31.75%
Public	24.20%	23.46%	21.69%	21.04%	20.45%	20.33%	21.27%	20.76%
Others	0.16%	0.16%	0.29%	0.26%	0.25%	0.25%	0.24%	0.20%
No. of Shareholders	3,10,403	4,03,669	4,59,605	4,51,929	4,49,216	4,55,243	4,49,665	4,46,086

DRREDDY key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	128	143	112	125	92	87	94	73
Inventory Days	242	224	250	242	219	291	275	268
Days Payable	124	109	118	121	127	148	120	103
Cash Conversion Cycle	246	257	243	247	184	230	250	239
Working Capital Days	125	116	95	89	95	130	63	39
ROCE %	12%	19%	15%	12%	19%	25%	26%	12%

DRREDDYUpdated 13 Oct 2026, 5:21

Dr. Reddy S Laboratories

DRREDDYUpdated 13 Oct 2026, 5:21

Market Cap

₹1,02,616Cr.

Current Price

₹1,229

High / Low

₹1,415/1,080

Stock P/E

155

ROE10.2%

ROCE12.1%

Book Value₹376

Face Value₹1.00

Dividend Yield0.65%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	5437	4	3210	234	237	2220	26	1639	19.69
Sep 2023	4839	6	3210	223	246	1601	25	1193	14.3
Dec 2023	4103	6	3447	228	246	632	25	475	5.7
Mar 2024	5105	6	3726	213	246	1339	23	1035	12.41
Jun 2024	5841	7	3888	218	250	1914	26	1417	16.99
Sep 2024	6696	28	3975	208	260	2641	29	1882	22.56
Dec 2024	5015	43	3823	235	265	1119	24	849	10.18
Mar 2025	5563	31	4120	414	264	1562	23	1201	14.39
Jun 2025	7810	19	3972	398	280	3936	25	2961	35.48
Sep 2025	4619	33	4138	364	295	516	25	387	4.64
Dec 2025	4283	41	4183	360	314	104	13	91	1.09
Mar 2026	3822	54	4322	567	318	-306	-28	-219	-2.63
Jun 2026	5137	73	4689	440	318	497	19	405	4.85

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	10011	64	7608	211	490	2060	18	1679	19.71
Mar 2016	10292	64	8219	317	650	1677	18	1374	16.11
Mar 2017	9720	57	7899	516	735	1544	10	1384	16.7
Mar 2018	9359	63	7990	164	774	697	19	567	6.83
Mar 2019	10626	57	8290	202	781	1701	25	1277	15.38
Mar 2020	11850	48	8967	730	789	2776	-6	2938	35.36
Mar 2021	13349	47	10212	801	835	3056	28	2186	26.29
Mar 2022	14405	38	11803	474	814	2224	27	1623	19.51
Mar 2023	16962	17	12724	568	923	3866	32	2613	31.38
Mar 2024	19484	22	13557	862	976	5791	25	4342	52.06
Mar 2025	23115	110	15691	961	1039	7236	26	5349	64.11
Mar 2026	20533	148	16615	1690	1207	4251	24	3220	38.58
TTM	17860	202	17332	1732	1245	812	—	663	7.95

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	26.63%
FIIs	20.67%
DIIs	31.75%
Public	20.76%
Others	0.2%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public	Others
Sep 2023	26.66%	28.19%	21.04%	23.93%	0.18%
Dec 2023	26.65%	28.62%	18.65%	25.89%	0.18%
Mar 2024	26.65%	29.13%	18.31%	25.73%	0.17%
Jun 2024	26.65%	27.68%	20.72%	24.78%	0.17%
Sep 2024	26.64%	27.53%	21.48%	24.2%	0.16%
Dec 2024	26.64%	26.85%	22.89%	23.46%	0.16%
Mar 2025	26.64%	25.75%	25.63%	21.69%	0.29%
Jun 2025	26.64%	25.33%	26.73%	21.04%	0.26%
Sep 2025	26.64%	24.69%	27.99%	20.45%	0.25%
Dec 2025	26.64%	22.34%	30.44%	20.33%	0.25%
Mar 2026	26.63%	21.14%	30.72%	21.27%	0.24%
Jun 2026	26.63%	20.67%	31.75%	20.76%	0.2%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	85	10549	3126	2696	16456	3249	488	3862	8856	16456
Mar 2016	85	11993	3085	2422	17585	4438	616	5076	7455	17585
Mar 2017	83	11518	2355	2491	16447	4842	540	3102	7963	16447
Mar 2018	83	11725	2589	2704	17100	4717	675	3636	8072	17100
Mar 2019	83	12601	1065	2499	16248	4683	400	3934	7231	16248
Mar 2020	83	15109	1457	2827	19476	4434	412	5486	9145	19476
Mar 2021	83	16900	1214	3431	21630	5844	901	4649	10235	21630
Mar 2022	83	18253	2205	3954	24496	6150	1200	4937	12208	24496
Mar 2023	83	20391	51	4850	25375	7195	924	7440	9815	25375
Mar 2024	83	24157	793	5326	30359	7589	1211	7321	14239	30359
Mar 2025	83	28773	3493	5941	38291	8232	2197	13194	14668	38291
Mar 2026	84	31282	5737	6500	43602	10730	1369	15595	15908	43602

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	1786	-2031	189	-56
Mar 2016	2747	-1919	-693	135
Mar 2017	1016	1430	-2582	-135
Mar 2018	1539	-1180	-304	54
Mar 2019	2762	-546	-2223	-8
Mar 2020	1839	-1689	-224	-74
Mar 2021	3514	-1454	-794	1266
Mar 2022	1339	-1990	506	-146
Mar 2023	5053	-3403	-2697	-1047
Mar 2024	3450	-3429	68	89
Mar 2025	4225	-5697	1591	118
Mar 2026	4660	-5760	1117	18

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	172	138	165	164	128	143	112	125	92	87	94	73
Inventory Days	223	234	256	258	242	224	250	242	219	291	275	268
Days Payable	93	99	110	147	124	109	118	121	127	148	120	103
Cash Conversion Cycle	302	273	311	274	246	257	243	247	184	230	250	239
Working Capital Days	99	82	112	98	125	116	95	89	95	130	63	39
ROCE %	16%	12%	11%	5%	12%	19%	15%	12%	19%	25%	26%	12%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of DR. REDDY S LABORATORIES (DRREDDY)?

The reported market capitalisation for DR. REDDY S LABORATORIES (DRREDDY) is ₹1,02,616Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of DRREDDY?

The current price shown for DR. REDDY S LABORATORIES (DRREDDY) on Fincrux is ₹1,229 with a 52-week high/low of ₹1,415/1,080.

What is the P/E ratio of DR. REDDY S LABORATORIES (DRREDDY)?

The stock P/E for DR. REDDY S LABORATORIES (DRREDDY) is 155 on Fincrux, with ROE at 10.2% and ROCE at 12.1%.

What were DRREDDY latest quarterly results?

For Jun 2026, DR. REDDY S LABORATORIES (DRREDDY) reported sales ₹5,137 Cr and net profit ₹405 Cr (figures in ₹ crore unless noted).

What are DRREDDY annual sales and net profit?

For TTM, DR. REDDY S LABORATORIES (DRREDDY) shows sales of ₹17,860 Cr and net profit of ₹663 Cr on the Fincrux profit & loss statement.

Who owns DR. REDDY S LABORATORIES (DRREDDY)?

Latest shareholding for DR. REDDY S LABORATORIES (DRREDDY) on Fincrux: Promoters 26.63% (Jun 2026), FIIs 20.67% (Jun 2026), DIIs 31.75% (Jun 2026), Public 20.76% (Jun 2026), Others 0.20% (Jun 2026).

Where can I find DR. REDDY S LABORATORIES (DRREDDY) financials?

DR. REDDY S LABORATORIES (DRREDDY) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show DRREDDY balance sheet and cash flow?

Yes. The DR. REDDY S LABORATORIES (DRREDDY) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 13 October 2026 at 5:21